A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
Chowdhury et al.
, A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
, Eurasian Journal of Medicine and Oncology, doi:10.14744/ejmo.2021.16263, NCT04434144
Small 116 patient RCT comparing ivermectin+doxycycline and HCQ+AZ, not showing a significant difference in time to PCR negative or symptom resolution. Time to symptomatic recovery was 5.93 days for ivermectin+doxycycline vs. 6.99 days for HCQ+AZ. Given the long half-life of HCQ and the lack of a loading dose, it may take several days for HCQ to reach therapeutic levels. 10% of HCQ+AZ patients were lost to followup (2x ivermectin+doxycycline). There is no comparison with a control group. NCT04434144 (history)
Abstract: DOI: 10.14744/ejmo.2021.16263
A Comparative Study on Ivermectin-Doxycycline and
Hydroxychloroquine-Azithromycin Therapy on
Abu Taiub Mohammed Mohiuddin Chowdhury,1
Guo Dan,1 Shuixiang He1
Md Rezaul Karim,3
Department of Gastroenterology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
Chakoria Upazilla Health Complex, Cox’s Bazar, Bangladesh
Biomedical Research Institute of Hubei University of Medicine, Shiyan, China
Department of Epidemiology and Health Statistics, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
Objectives: We investigated the outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy in mild to moderate COVID19 patients.
Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mg
BID for ten days in group A, and Hydroxychloroquine 400mg for the first day, then 200mg BID for nine days + Azithromycin 500mg daily for five days in group B (Control group). RT-PCR for SARS-CoV-2 infection was repeated in all symptomatic patients on the second day onward without symptoms. Repeat PCR was done every two days onward if the
result found positive. Time to the negative PCR and symptomatic recovery was measured for each group.
Results: All subjects in Group A reached a negative PCR, at a mean of 8.93 days, and reached symptomatic recovery, at a
mean of 5.93 days, with 55.10% symptom-free by the fifth day. In group B, 96.36% reached a negative PCR at a mean of
9.33 days and were symptoms-free at 6.99 days. In group A 31.67% of patients expressed symptoms caused by medication, this was 46.43% in group B.
Conclusion: The combination therapy of Ivermectin-Doxycycline showed a trend towards superiority to the combination of Hydroxychloroquine-Azithromycin for mild to moderate COVID19 disease.
Keywords: Azithromycin, Bangladesh, COVID-19, Doxycycline, Hydroxychloroquine, Ivermectin, randomized controlled
Cite This Article: Mohiuddin Chowdhury ATM, Shahbaz M, Karim MR, Islam J, Dan G, He S. A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients. EJMO 2021;5(1):63–70.
oronavirus disease 2019 (COVID-19) is a global pandemic declared by the world health organization
(WHO). Over ninety million people have already been
infected by severe acute respiratory syndrome‐corona-
virus‐2 (SARS-CoV-2), and billions have been affected by
the socioeconomic squeal. As SARS-CoV-2 is a novel virus,
there are no proven treatment options yet. Early treatment
before the disease becomes severe would be optimal. The
Address for correspondence: Shuixiang He, MD; PhD. Department of Gastroenterology, First affiliated hospital of Xi’an Jiaotong University,
Xi’an, Shaanxi, P.R. China
Phone: 008613991380928 Email: firstname.lastname@example.org
Abu Taiub Mohammed Mohiuddin Chowdhury, MD. Department of Gastroenterology, First Affiliated Hospital of Xi’an Jiaotong University,
Xi’an, Shaanxi, P.R. China
Phone: 008801817711079; 008615529366232 E-mail: email@example.com
Submitted Date: January 21, 2021 Accepted Date: February 15, 2021 Available Online Date: February 25, 2021
Copyright 2021 by Eurasian Journal of Medicine and Oncology - Available online at www.ejmo.org
OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.